Clinical efficiency of Perindopril arginin in hypertensive patients with left ventricular hypertrophy

Abstract

To assess the antihypertensive and organoprotective efficiency of Perindopril arginin in hypertensive patients with left ventricular hypertrophy (LVH). Design and methods. 12-months study involved 59 patients with non-target blood pressure (BP) and LVH divided into 2 groups. Prestarium A (group 1) and enalapril (group 2) were administered; if necessary the other antihypertensive medications were added. Echocardiography and albuminuria assessment were performed regularly during the follow-up. Results. Within 12 months in group 1 systolic BP (SBP) was decreased by 22 % and the target level was achieved in 92 % of patients, diastolic BP (DBP) was decreased by 14 % and the target values were achieved in 91 % of patients. In group 2 SBP was decreased by 16 %, DBP was decreased by 10 % (the target levels were achieved in 83 % of patients). Only patient of the group 1 demonstrated significant reduction of urine albumin excretion. Left ventricular myocardium mass index reduction was found in both groups, however only patients of the group 1 showed the improvement of diastolic function. Conclusion. Prestarium A contributes to the effective BP control, regression of left ventricle hypertrophy, improvement of left ventricle diastolic function and endothelium function.